Article
Toxic profile of marinobufagin from poisonous Amazon toads and antitumoral effects on human colorectal carcinomas
Registro en:
FERREIRA, Paulo Michel Pinheiro et al. Toxic profile of marinobufagin from poisonous Amazon toads and antitumoral effects on human colorectal carcinomas. Journal of Ethnopharmacology, v. 310, p. 1-13, 2023.
0378-8741
10.1016/j.jep.2023.116406
Autor
Ferreira, Paulo Michel Pinheiro
Sousa, Lívia Queiroz de
Sousa, Rayran Walter Ramos de
Rodrigues, Domingos de Jesus
Monção Filho, Evaldo Dos Santos
Chaves, Mariana Helena
Vieira Júnior, Gerardo Magela
Rizzo, Márcia dos Santos
Filgueiras, Lívia Alves
Mendes, Anderson Nogueira
Lima, Daisy Jereissati Barbosa
Pessoa, Cláudia
Sousa, João Marcelo de Castro E.
Rodrigues, Ana Carolina Borges da Cruz
Soares, Milena Botelho Pereira
Bezerra, Daniel Pereira
Resumen
Fundação ao de Amparo à Pesquisa do Estado do Piauí (FAPEPI).
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq).
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior” (CAPES). Ethnopharmacological relevance: South Americans natives have extensively used the toad "kururu" to reduce/treat skin infections, cutaneous lesions and sores. They release secretions rich in bufadienolides, polyhydroxy steroids with well-documented cardiotonic and antiproliferative actions, but in vivo antitumoral evaluations in mammals are rare, and toxicological safety has been left in second place. Aims of the study: This investigation used in silico, in vitro and in vivo tools to evaluate acute and subacute toxic effects of marinobufagin and the anticancer action in tumor-bearing mice models. Materials and methods: Initially, in silico toxic predictions were performed, followed by in vitro assays using human and murine normal and tumor lines. Next, acute and subacute studies on mice investigated the behavior, hematological and intestinal transit profile and antitumoral activity of marinobufagin in sarcoma 180- and HCT-116 colorectal carcinoma-transplanted mice for 7 and 15 days, respectively. Ex vivo and in vivo cytogenetic assays in Sarcoma 180 and bone marrow cells and histopathological examinations were also executed. Results: In silico studies revealed ecotoxicological effects on crustaceans (Daphnia sp.), fishes (Pimephales promelas and Oryzias latipes), and algae. A 24-h marinobufagin-induced acute toxicity included signals of central activity, mainly (vocal frenzy, absence of body tonus, increased ventilation, ataxia, and equilibrium loss), and convulsions and death at 10 mg/kg. The bufadienolide presented effective in vitro cytotoxic action on human lines of colorectal carcinomas in a similar way to ouabain and tumor reduction in marinobufagin-treated SCID-bearing HCT-116 heterotopic xenografts. Animals under subacute nonlethal doses exhibited a decrease in creatinine clearance with normal levels of blood urea, probably as a result of a marinobufagin-induced renal perfusion fall. Nevertheless, only minor morphological side effects were identified in kidneys, livers, hearts and lungs. Conclusions: Marinobufagin has in vitro and in vivo anticancer action on colorectal carcinoma and mild and reversible alterations in key metabolic organs without direct chemotherapy-induced gastrointestinal effects at subacute exposure, but it causes acute ataxia, equilibrium loss, convulsions and death at higher acute exposure. 31-12-2030